3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Temozolomide
53
Bevacizumab
45
Radiotherapy
28
Radiosurgery
21
Carboplatin
14
Erlotinib Hydrochloride
11
Radiation
10
pembrolizumab
9
Magnetic Resonance Spectroscopy
9
Etoposide
9
Vorinostat
8
Trastuzumab
8
Irinotecan
8
Sunitinib
7
Sorafenib
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Lapatinib
7
Capecitabine
7
dabrafenib
6
Ipilimumab
6
Imatinib Mesylate
6
Cyclophosphamide
6
Sirolimus
5
Hydroxyurea
5
Everolimus
5
Bortezomib
5
temsirolimus
4
cabozantinib
4
binimetinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Brain Neoplasms
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts